OZR Backup mandate: IgE-mediated Autoimmunity in Atopic Dermatitis; From the first stages of autoimmunity to therapeutic immunomodulation

Project Details


In patients with atopic dermatitis (AD), increased risk of co-morbid autoimmune diseases was found. Additionally, IgE-mediated autoimmunity directed to the skin has been demonstrated in patients with moderate/severe AD, suggesting a role for autoreactive IgE antibodies and self-reactive T cells in AD pathophysiology and an association with disease severity.
In the present project, we hypothesize that autoreactive IgE antibodies can be present already shortly after birth, and that heredity patterns and environmental exposure may explain these findings. This projects aims at investigating the very first stages of IgE-mediated autoimmunity in newborns. Next, we postulate that
autoreactive IgE increases prior to skin exacerbations, suggesting an aggravating factor for disease activity. Therefore, we assume that currently available treatments with monoclonal antibodies not only improve AD symptoms, but also autoreactive IgE levels. Therefore, we aim to evaluate the relation between disease activity and the levels of autoreactive IgE before and after treatment. Finally, we presume that modulation of the PD-1/PD-L1 axis could be a potential target for therapy in these patients. Ultimately, we aim to modulate the PD-1/PD-L1 axis as novel target for therapy in a mouse model. This project will increase current insights of AD-pathophysiology with IgE-mediated autoimmunity and open new doors for disease endotyping and precision therapy with direct consequences for diagnosis and treatment
Effective start/end date1/10/2130/09/23

Flemish discipline codes

  • Allergology
  • Adaptive immunology
  • Inflammation
  • Autoimmunity
  • Innate immunity


  • Atopic dermatitis
  • Autoreactivity
  • IgE-mediated autoimmunity